Ocular Therapeutix (NASDAQ:OCUL) Issues Earnings Results, Misses Estimates By $0.06 EPS

Ocular Therapeutix (NASDAQ:OCUL) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.06), FiscalAI reports. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%. The firm had revenue of $12.87 million for the quarter, compared to analysts’ expectations of $14.27 million. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. The company’s revenue for the quarter was down 11.5% on a year-over-year basis.

Here are the key takeaways from Ocular Therapeutix’s conference call:

• Ocular said it remains on track to submit AXPAXLI’s wet AMD NDA in Q4 2026, following a positive pre-NDA meeting and alignment with the FDA on its submission plan. The company expects the package to include SOL-1 efficacy, interim SOL-R safety, and repeat-dose data from more than 300 patients.
• Management highlighted SOL-1 results showing durable disease control after one injection, including about two-thirds of patients remaining rescue-free through week 52 in a challenging patient population. Based on these findings, Ocular is extending SOL-X dosing intervals from 24 to 48 weeks to study annual maintenance treatment.
• Ocular changed SOL-R’s primary efficacy endpoint from week 56 to week 40 so all patients can complete the assessment before the planned safety-data unmasking; the company said the change is FDA-aligned and carries a minimal alpha penalty. SOL-R remains masked through week 96, with topline results expected in Q1 2028.
• The company is building launch capabilities and said it has held pre-approval discussions with all of its top-priority payer accounts, covering about 84% of commercial lives. Management believes AXPAXLI could address the maintenance-treatment segment, though approval and adoption are not assured.
• Ocular ended Q3 with $530.6 million in cash and expects its runway to extend into 2028, but that estimate excludes the full anticipated costs of commercializing AXPAXLI.

Ocular Therapeutix Trading Up 3.9%

Shares of NASDAQ:OCUL opened at $6.85 on Tuesday. The firm has a fifty day moving average of $8.33 and a two-hundred day moving average of $9.00. Ocular Therapeutix has a 12-month low of $6.00 and a 12-month high of $16.44. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Peter Kaiser sold 9,990 shares of the company’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $7.05, for a total value of $70,429.50. Following the transaction, the insider directly owned 254,388 shares of the company’s stock, valued at approximately $1,793,435.40. This represents a 3.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Anderman sold 11,984 shares of the stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $7.29, for a total value of $87,363.36. Following the sale, the insider owned 140,484 shares of the company’s stock, valued at approximately $1,024,128.36. This represents a 7.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 98,090 shares of company stock worth $787,920 over the last 90 days. 3.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

OCUL has been the topic of a number of research analyst reports. Wall Street Zen upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research raised Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a research note on Thursday, October 15th. Royal Bank Of Canada restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, September 29th. Finally, Chardan Capital restated a “buy” rating and set a $23.00 price objective on shares of Ocular Therapeutix in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.33.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Ocular Therapeutix plans to submit an NDA for AXPAXLI in the fourth quarter of 2026. Its $530.6 million cash balance is expected to fund operations into 2028, reducing near-term financing concerns. Article: AXPAXLI filing plan and cash runway
• Neutral Sentiment: Insider Namrata Saroj sold 35,370 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated reason makes the transaction less indicative of a discretionary view on OCUL. SEC insider transaction filing
• Neutral Sentiment: The company appointed Riad Sherif to its board of directors, a governance change with no immediate, clear financial impact. Article: Board appointment
• Negative Sentiment: Third-quarter results missed expectations: the company reported a $0.42-per-share loss versus the expected $0.36 loss, while revenue of $12.87 million fell short of the $14.27 million consensus and declined 11.5% year over year. Article: Third-quarter earnings miss
• Negative Sentiment: Reports also pointed to costs of advancing AXPAXLI and declining DEXTENZA sales, highlighting pressure on near-term operating performance. Article: Pipeline costs and DEXTENZA sales

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.

Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

The company was founded in 2006 and serves the U.S.